CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, August 1, 2025 to report i ...

CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, August 1, 2025 to report ...

Moderna (NasdaqGS:MRNA) recently experienced significant index changes, with the company being added to the Russell Midcap and Midcap Value indexes, while being dropped from several others. Over the ...

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...

Moderna's MRNA +4.30% Get Free Report short percent of float has risen 3.2% since its last report. The company recently reported that it has 65.59 million shares sold short, which is 23.56% of all ...

Major U.S. equities indexes were little changed at midday Wednesday after a report on wholesale inflation showed a surprising ...

The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and discussed a 50% levy on imported copper.

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010 ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.